The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis

Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy with a variable clinical outcome. Biomarkers of CLL progression are required for optimising prognosis and therapy. The Inhibitor of Bruton’s tyrosine kinase—isoform α (IBTKα) gene encodes a substrate receptor of Cullin 3-depend...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Death Dis
Autori principali: Albano, Francesco, Chiurazzi, Federico, Mimmi, Selena, Vecchio, Eleonora, Pastore, Arianna, Cimmino, Clementina, Frieri, Camilla, Iaccino, Enrico, Pisano, Antonio, Golino, Gaetanina, Fiume, Giuseppe, Mallardo, Massimo, Scala, Giuseppe, Quinto, Ileana
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5849039/
https://ncbi.nlm.nih.gov/pubmed/29317636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0026-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi